Send to

Choose Destination
J Neurooncol. 2007 Jun;83(2):173-9. Epub 2007 Jan 12.

MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities.

Author information

INSERM, U711, Biologie des Interactions Neurones & Glie, Université Pierre et Marie Curie, Faculté de Médecine, Paris, France.


MGMT promoter methylation, which has been correlated with the response to alkylating agents, was investigated in a retrospective series of 219 glioblastomas (GBMs) treated with various modalities. MGMT methylation had no impact on survival for the whole group, but showed a significant advantage (17.1 months vs. 13.1) for patients treated with RT+ adjuvant chemotherapy (relative risk of death (RR) = 0.53; P = 0.041), particularly when patients received CT during the course of RT (MS = 19.9 months vs. 12.5 months; RR = 0.227, P = 0.001). This suggests that the prognostic impact of MGMT methylation is dependent on therapeutic modalities and schedules. MGMT methylation was not correlated with the main molecular alterations, such as 10q loss and p53 expression.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center